Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Armstrong

Showing results (11-20 of 350) with videos related to

Pageof 35
Sort By:
Oncology (Williston Park, N.Y.)|October 18, 2014
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yetAndrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|April 12, 2017
Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancerAndrew J Armstrong
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
New treatment options in castration-resistant prostate cancerAndrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|March 15, 2022
Highlights in advanced prostate cancer from the 2021 Genitourinary Cancers Symposium: commentaryAndrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
Epithelial-mesenchymal transition in cancer progressionAndrew J Armstrong
The Lancet. Oncology|March 29, 2012
The STAMPEDE trial and celecoxib: how to adapt?Andrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancerJing Li, Andrew J Armstrong
European Urology|March 10, 2012
Objective evaluation of bone metastases in prostate cancer: to what end?Guru Sonpavde, Andrew J Armstrong
Nature Clinical Practice. Urology|May 13, 2006
Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?Andrew J Armstrong, Mario Eisenberger
European Urology|February 17, 2021
Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?Susan Halabi, Andrew J Armstrong
Pageof 35

Showing results (11-20 of 350) with videos related to

Sort By:
Pageof 35
Oncology (Williston Park, N.Y.)|October 18, 2014
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yetAndrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|April 12, 2017
Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancerAndrew J Armstrong
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
New treatment options in castration-resistant prostate cancerAndrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|March 15, 2022
Highlights in advanced prostate cancer from the 2021 Genitourinary Cancers Symposium: commentaryAndrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
Epithelial-mesenchymal transition in cancer progressionAndrew J Armstrong
The Lancet. Oncology|March 29, 2012
The STAMPEDE trial and celecoxib: how to adapt?Andrew J Armstrong
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancerJing Li, Andrew J Armstrong
European Urology|March 10, 2012
Objective evaluation of bone metastases in prostate cancer: to what end?Guru Sonpavde, Andrew J Armstrong
Nature Clinical Practice. Urology|May 13, 2006
Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?Andrew J Armstrong, Mario Eisenberger
European Urology|February 17, 2021
Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?Susan Halabi, Andrew J Armstrong
Pageof 35